Two Messages Arrive in the Same Week
As Americans voted on Tuesday, 3 November 2026, they were hearing two very different messages about the cost of medicine. From the White House and from President Donald Trump, the message was one of victory: the United States, the administration says, has gone from paying the highest drug prices in the world to paying the lowest. From independent health analysts, the message was more complicated: millions of older Americans who buy stand-alone Medicare prescription drug coverage could face sharply higher monthly premiums next year if they stay in their current plans. Both messages were circulating on Election Day, and neither, on its own, tells the whole story.
The White House version was repeated on 3 November itself, when the official White House account shared a claim that the country once had the highest drug prices in the world and now has the lowest. It was a short, confident formulation, of the kind designed to travel on social media, and it echoed remarks the president had made at campaign events in the days before the election. At a rally in Ohio on 28 October, for example, he told supporters that pharmaceuticals were going well, that hundreds of billions of dollars were involved, and that Republican candidates should win on that issue alone. The claim is a political argument as much as a factual one: it asks voters to judge the administration by a single, memorable comparison with the rest of the world.
The other message came from KFF, a nonprofit health research organisation, in an analysis published on 30 October. KFF projected that the average monthly premium for stand-alone Medicare Part D drug plans would rise to 51 dollars in 2027, up 50 percent from 34 dollars in 2026, if current enrollees do not switch to lower-premium plans during open enrolment, which runs through 7 December. That projection does not describe a drug price in a shop. It describes a premium, the monthly amount a person pays for insurance coverage, and it applies to a specific group: people who buy stand-alone drug plans rather than getting drug coverage through Medicare Advantage. Understanding that distinction is essential, because much of the confusion on Election Day came from comparing different things as if they were the same.
How the White House Drug Prices Claim Compares With Medicare Bills
To compare the White House claim with what Medicare enrollees actually pay, it helps to separate three different costs that are often run together in political debate. The first is the list price or negotiated price of a medicine itself. The second is the premium a person pays each month for drug insurance. The third is what a person pays at the pharmacy counter, including deductibles and other cost-sharing. A policy can lower one of those costs while another rises, and a claim about one does not automatically prove anything about the others.
The administration’s claim rests mainly on its most-favoured-nation pricing agreements. Under that approach, participating drug manufacturers agree to align American prices with the lowest prices paid in a basket of comparable developed countries. The White House has said that 26 drugmakers, covering about 90 percent of the branded American market, have signed such agreements, and it has projected savings of more than 600 billion dollars. It has also pointed to TrumpRx, a government-linked purchasing channel, saying it has saved patients more than 700 million dollars, and it has said that all state Medicaid programmes now receive most-favoured-nation prices. Those are the administration’s own figures and projections, and they have not been independently verified as a single total.
Independent checks have found a more mixed picture. KFF compared TrumpRx prices for 32 brand-name drugs with prices in other wealthy countries and found that only five were the lowest in the world, while 13 were the highest. Other comparisons, including reporting based on a Reuters comparison with Britain’s National Health Service, found that about a third of sampled drugs were cheaper in Britain. That does not mean the agreements have had no effect, and it does not mean every drug is more expensive. It does mean that the broad claim that Americans now pay the lowest prices anywhere, for medicines in general, is not supported by those drug-by-drug comparisons, and it should be treated as an administration claim rather than as an established fact.
At the same time, prescription drug spending overall remains very high. Industry figures cited in recent reporting put American prescription drug spending at 915 billion dollars in 2025, a rise of 12.7 percent, with a projection above one trillion dollars in 2026. Prices for the 25 most widely used brand-name drugs have risen by an average of 81 percent since their launches, according to the AARP Public Policy Institute. Those figures describe a system, not a single deal, and they help explain why affordability remains a leading concern for voters even when an administration can point to individual agreements or individual price falls.
What KFF Actually Found About 2027 Premiums
KFF’s 30 October analysis is specific, and its conditions matter. It looked at stand-alone Part D plans, which cover about 25 million people, separate from the roughly 31 million people who get drug coverage through Medicare Advantage plans. It weighted premiums by June 2026 enrolment and assumed that people stay in their current plans. On that basis, the average monthly premium rises from 34 dollars to 51 dollars, an increase of 17 dollars, or 50 percent. KFF estimated that about 10.4 million stand-alone enrollees who do not receive low-income subsidies, about 76 percent of that group, would pay more next year if they stay put.
The distribution of increases is at least as important as the average. KFF found that more than 4 million enrollees are currently in plans that charge no premium, and that no zero-premium stand-alone plans will be offered in 2027, so all of those people will pay something next year. About 2.4 million people could see their monthly premium rise by more than 50 dollars, a far larger jump than in the previous year, when only about 38,000 people faced an increase that large. One Virginia enrollee cited by KFF Health News was told his plan would rise from 39.60 dollars a month to 121.90 dollars. Averages hide those individual shocks, and individual shocks are what people notice when an enrolment notice arrives.
KFF also projected higher cost-sharing. The average stand-alone plan deductible was projected to rise from 540 dollars to 643 dollars, and the average drug deductible in Medicare Advantage plans from 360 dollars to 489 dollars. The standard Part D deductible was set to rise from 615 dollars to 700 dollars, and the annual out-of-pocket cap from 2,100 dollars to 2,400 dollars. Those are not small changes for people on fixed incomes, and they help explain why a debate about premiums can feel more urgent to retirees than a debate about international price comparisons, however important the latter may be in the long run.
It is also important to note what KFF did not say. Its projection is not a prediction that every Medicare enrollee will pay 51 dollars, and it is not a claim that no one can do better by switching plans. KFF itself noted that many enrollees face modest increases or even reductions, and that the real average is likely to end up lower once people switch during open enrolment. The 50 percent figure describes what happens if people do nothing. That is a meaningful warning, because many people do nothing, but it is not the same as a final bill for every enrollee.
Why the Government’s Own Number Looks So Different
The Centers for Medicare and Medicaid Services, the federal agency that runs Medicare, published a very different headline figure in late September. It said the average monthly premium for stand-alone Part D plans would rise by less than one dollar, from 35.09 dollars in 2026 to 36 dollars in 2027. It also said the drug portion of Medicare Advantage premiums would fall by 38 percent, from 11.32 dollars to about 7 dollars. The agency dismissed predictions of a premium spike as speculation and misleading reports, and said the Part D market was returning to normal.
How can two careful-looking numbers differ by so much? The answer lies mainly in what each number measures. The CMS figure describes the average premium of the plans on offer, weighted by later enrolment assumptions, and it implicitly assumes that many people will move to cheaper plans. The KFF figure describes what current enrollees would pay if they stay where they are, weighted by June enrolment. Both can be arithmetically defensible, and both can mislead if quoted without their conditions. A flat average for plans on sale can coexist with a steep rise for people who renew automatically, and a steep stay-in-place average can coexist with a better deal for people who shop around.
The policy background to the gap is the end of a subsidy programme. The Part D Premium Stabilisation Demonstration, set up under the previous administration after the Inflation Reduction Act capped out-of-pocket drug spending and shifted more of the cost of expensive drugs onto insurers, was ended early by CMS in July 2026, after two years of a planned three. KFF estimated the programme was worth about 9.8 billion dollars across 2025 and 2026 and had cut the average premium by about 16 dollars a month. CMS Administrator Mehmet Oz has described the programme as an insurance-industry bailout and has said most enrollees would see rises of less than 10 dollars a month, with some paying less. The agency said insurers’ 2027 bids showed they no longer needed the support. Critics, including House Democrat Frank Pallone, have asked the Government Accountability Office to investigate the administration’s savings claims, saying key details of the pricing agreements have not been disclosed. Those are allegations and requests for investigation, not findings, and they should be reported as such.
For voters trying to make sense of the dispute, the practical lesson is not to trust either headline in isolation. The CMS number is most useful for understanding the market as a whole. The KFF number is most useful for understanding the risk of doing nothing. Neither number, on its own, answers the question that matters most to an individual enrollee: what will my plan cost next year, and is there a cheaper plan that covers my medicines?
What the Pricing Deals Do, and What They Do Not Do
The most-favoured-nation deals, as described by the administration and by independent analysts, mainly affect Medicaid and cash purchases, and they leave Medicare and private insurance prices largely unchanged in the short term, according to pharmacy-trade coverage summarised in recent reporting. That is a crucial limitation. Medicaid covers lower-income Americans, and cash buyers are a relatively small group. Most older Americans get drug coverage through Medicare, either stand-alone Part D or Medicare Advantage, and most working-age Americans get it through employer or marketplace insurance. A deal that lowers a price for one channel does not automatically lower the premium or the pharmacy bill in another.
The deals also do not waive the Food and Drug Administration’s safety and effectiveness standards, and they do not, by themselves, make a medicine available at a new price the next day. Agreements need to be implemented, prices need to be reflected in formularies and pharmacy systems, and patients need to be able to find the lower price when they need the medicine. The administration’s projection of more than 600 billion dollars in savings is a long-term, system-wide estimate, not a cheque that has already arrived in patients’ pockets. Independent analysts have said the figure has not been checked against a published actuarial model, which is why it should be described as a projection, not as money already saved.
There are also savings coming from an earlier law that are sometimes confused with the current deals. Prices negotiated under the Inflation Reduction Act for 15 additional drugs, including Ozempic and Wegovy, take effect in 2027, and CMS has estimated they will save enrollees 685 million dollars out of pocket. Those savings belong to a programme begun under the previous administration, and crediting them to the current pricing deals would be misleading. Equally, dismissing the current deals entirely because they have not yet transformed every price would be misleading in the other direction. The honest position, on the evidence available on Election Day, is that the deals are real, their scope is contested, and their full effect is not yet measurable.
Prescription drug prices did fall by 3.1 percent in the year ending in July, according to figures cited in recent coverage, but experts quoted in that coverage said it was too early to know how much of that fall the new deals caused, as opposed to other market and policy factors. That caution applies to both sides of the debate. Supporters should not claim a single month or a single deal as proof of a transformation. Critics should not claim that a premium rise in one part of Medicare proves that no drug price has fallen anywhere.
Open Enrolment: The Decision That Matters Most Right Now
For millions of Medicare enrollees, the most important date after Election Day is not a political deadline but a practical one: 7 December, when open enrolment ends. The plan chosen by then will generally set drug coverage costs for 2027, with new coverage starting on 1 January. That gives enrollees a window, but only if they use it. People who let coverage renew automatically are the people KFF’s 50 percent projection describes. People who compare plans, check that their medicines are covered, and look at deductibles as well as premiums, may find a very different result.
The range of premiums on offer illustrates why shopping matters. KFF found that average monthly premiums for the eight national stand-alone plans were projected to range from around 6 dollars to 204 dollars in 2027. The highest-premium national plan, United’s AARP Medicare Rx Preferred, was projected to average 204.50 dollars a month, up from 126 dollars in 2026. A person in that plan who stays put faces a very different year from a person who moves to a lower-premium plan that still covers their medicines. The trade-off is not always simple: a cheaper premium can mean a narrower formulary, a higher deductible, or a pharmacy network that is less convenient. Enrollees need to check all three, not just the monthly headline.
Medicare Advantage enrollees face a different set of trade-offs. KFF projected the average drug premium in those plans at about 9 dollars a month in 2027, an increase of less than 2 dollars, and CMS projected a fall in the drug portion of Advantage premiums. That does not mean Advantage coverage is automatically better: those plans often have different networks, prior authorisation rules and out-of-pocket limits for other care. The comparison that matters is the total cost and coverage for a person’s own medicines and doctors, not a national average for one component of one type of plan.
Advocacy groups and official helplines both advise the same basic steps: list current medicines and doses, check each plan’s formulary, compare premiums, deductibles and pharmacy costs together, and do not assume that last year’s best plan is still the best plan. That advice is unglamorous, and it does not fit into a social media post, but it is where the abstract debate about drug prices becomes concrete for households.
Affordability Politics on Election Day, Without Claiming a Result
Healthcare affordability was one of the leading concerns for voters heading into the 3 November midterms, alongside the broader cost of living. Higher insurance premiums, prescription costs and out-of-pocket expenses have added to household spending, and polling in the final days suggested that voters trusted neither party automatically on the issue. The White House’s drug-price claim was, in that context, an attempt to turn a complex policy area into a clear electoral argument: we fixed this, and you should judge us on it.
The KFF analysis, arriving days before the vote, complicated that argument without settling it. It gave critics a concrete number to quote, and it gave journalists a reason to ask whether a claim about world prices matched the bills arriving in mailboxes. It also gave the administration a chance to respond, which it did, by pointing to its own CMS figures and by arguing that the market was normalising after a subsidy that had distorted premiums. Voters, in other words, were not presented with a single agreed fact but with competing numbers, each with its own assumptions, and each requiring a judgement about which assumption fits real life.
No election result is claimed in this article, and none should be inferred from the drug-price debate alone. Midterms are decided by many issues, by turnout, by local races and by candidates, not by a single policy claim. What can be said is that the drug-price argument will not end on Election Day, whatever the outcome in Congress. Open enrolment runs until 7 December, premiums for 2027 are already set in plan filings, and the pricing agreements will be tested in the months ahead by whether patients actually pay less at the pharmacy, not only by whether press releases say they will.
That test will be measurable, in part, by data that has not yet arrived: actual 2027 enrolment choices, actual pharmacy spending, and actual implementation of the pricing deals. Until then, the responsible summary is a divided one. The administration has signed pricing agreements it describes as historic, and independent drug-by-drug checks have not confirmed the broadest version of its claim. Stand-alone Medicare premiums are projected to rise sharply for people who stay put, while the government says the market average will barely move. Both statements can be true about different groups, and the group that matters most to any reader is their own. On Election Day, that distinction, more than any slogan, was the most useful thing a voter could carry into the polling place and, afterwards, into the open enrolment window.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from KFF, Cobb County Courier and Medical Daily.